Drector, Hematologic Malignancy Service

Houston, Texas (US)
Competitive salary and benefits
Jul 29, 2019
Aug 28, 2019
Full Time

Director, Hematologic Malignancy Service
Dan L Duncan Comprehensive Cancer Center
and Department of Medicine
Baylor College of Medicine and Baylor St. Luke’s Medical Center
Houston, Texas

The Dan L Duncan Comprehensive Cancer Center and the Department of Medicine at Baylor College of Medicine in Houston, Texas, are recruiting an experienced hematologist or medical oncologist clinician or clinician scientist to direct the hematologic malignancy service in the Cancer Center and at Baylor St. Luke’s Medical Center Hospital.  The successful candidate will be an established investigator with a national reputation at the late Associate or full Professor level. Baylor College of Medicine and the NCI-designated Comprehensive Cancer Center are affiliated with five major teaching hospitals in the Texas Medical Center including Baylor St Luke’s Medical Center, The Ben Taub General Hospital and the Michael E DeBakey VA Medical Center.  The 450 members of the Dan L. Duncan Cancer Center include 200 research members who generate more than $180M annually in cancer related research funding including nearly $50M from the NCI. Two long-term SPORE grants in breast cancer and lymphoma, a third SPORE with MD Anderson in Brain tumors, and a Leukemia Lymphoma SCOR Grant are among 44 multi-investigator awards.  Cancer researchers in Texas can apply for research funding to the Cancer Prevention and Research Institute of Texas (a state program charged with supporting innovative cancer research and prevention services in Texas with $3 billion in funding over 10 years). Generous recruitment awards are also available on a competitive basis from CPRIT (up to $6M for an established investigator).    The Center includes seven outstanding integrated Research Programs in Breast Cancer, Cancer Cell and Gene Therapy, Nuclear Receptor, Transcription and Chromatin Biology, Pediatric Oncology, Cancer Prevention and Population Science, Cell Signaling and Metabolism, and Mechanisms of Cancer Evolvability.  Several new initiatives are in development including programs in thoracic malignancies, hematologic malignancies, GU cancers, early phase clinical trials, and precision cancer medicine and proteogenomics. Eleven Shared Resources are available to Cancer Center members, and the Human Genome Sequencing Center, the Center for Drug Discovery, and the Therapeutic Innovation Center focusing on drug development in gene control targets are additional unique resources.  The Center is the recipient of a $100M naming gift from the Duncan family.  Interested candidates will have an MD or MD/PhD degree and should be Board Certified in hematology and/or oncology. Applications should include a letter outlining the candidate’s academic accomplishments and interests in addition to a curriculum vitae and the names of four references. 

Baylor College of Medicine is an Equal Opportunity/Affirmative Action/Equal Access Employer.

Please send application to:

Martha P. Mims, M.D., Ph.D
Chief, Section of Hematology/Medical Oncology
Professor of Medicine
Baylor College of Medicine
One Baylor Plaza, BCM 187
Houston, Texas 77030

C. Kent Osborne, M.D.
Director, Dan L Duncan Comprehensive Cancer Center
Professor of Medicine and Molecular and Cellular Biology
Baylor College of Medicine
One Baylor Plaza, BCM 305
Houston, Texas   77030